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We pursued an association between hypertension and gliomas by investigating whether antihypertensive drugs (AHD) are associated
with an increased glioma risk by a population-based nested case–control study using the PHARMO database; this links dispensing
records of prescription drugs to hospital discharge data on an individual basis. Pathological data were derived from the Dutch
nationwide registry of histo- and cytopathology. A total of 306 glioma cases incident between 1997 and 2003 were matched to 1108
controls for year of birth, sex, geographical region and duration of follow-up. Exposure was defined as cumulative duration of AHD
use and, in an alternative analysis, as cumulative dose. We estimated the magnitude of the association with conditional logistic
regression analysis. Cumulative use of any AHD for more than 6 months was associated with an increased risk of glioma (OR 1.45;
95% CI 1.03–2.04). After stratification for different groups of AHD, no significantly increased risk of glioma was found for any class of
AHD. After excluding a latency period of 3 years before the date of diagnosis, no association was found. In conclusion, the use of
AHD seems to be associated with an increased risk of glioma, but this is probably not causal.
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Although gliomas are the most common type of primary brain
tumour, they are nevertheless relatively rare. In the Netherlands,
world-standardised incidence rates of glioma are 6.5 per 100000
person-years for male and 4.4 for female subjects (van der Sanden
et al, 1998). The aetiology of glioma remains largely unclear and
ionising radiation is the only established environmental risk factor,
but the exposure rate is low (Ron et al, 1988; Karlsson et al, 1998).
Some rare genetic disorders exist in which patients have an
increased risk of glioma and a variety of other cancers (Louis and
von Deimling, 1995; Melean et al, 2004).
Previously, we found a significantly higher prevalence of
hypertension in glioma patients in a population-based case–control
study in the Eindhoven Cancer Registry (Houben et al,2 0 0 4 ) .W e
hypothesised that one possible mechanism for this association is
through potentially neurocarcinogenic effects of antihypertensive
drugs (AHD) or their metabolites. To test the hypothesis of a
glioma-inducing effect of AHD, we conducted a population-based
nested case–control study with prospectively collected automated
pharmacy data, linked to morbidity and pathology data.
MATERIALS AND METHODS
Setting
We used the PHARMO record linkage system, a database that since
1985 has linked dispensing records of prescription drugs from a
representative sample of Dutch community pharmacies to hospital
discharge data on an individual basis (Herings, 1993). These
pharmacies are scattered over the country and currently cover data
of more than two million residents, equivalent to 12% of the Dutch
population. Participants enter the database when their first
prescription is filled in a PHARMO community pharmacy, and
they are followed thereafter. The recorded information of each
drug includes the Anatomical Therapeutic Chemical (ATC) code
(WHO, 1990), the dispensing date, the quantity of the drug, the
prescribed daily dose, and the estimated duration of use. Because
almost all persons designate a single pharmacy to fill their drug
prescriptions, dispensing histories are virtually complete (Lau
et al, 1997).
Drug dispensing histories are linked to hospital discharge
records from the Dutch Medical Register (LMR), using a validated
and reliable probabilistic algorithm (Herings, 1993). The LMR
comprises all hospital admissions in the Netherlands and includes
dates of admission and discharge, discharge diagnoses, comorbi-
dity and performed medical procedures. All diagnoses are coded
according to the International Classification of Diseases, ninth
edition clinical modification (ICD-9-CM). Since 1991, the primary
diagnosis is determined by the specialist who treated the patient.
Other sources of morbidity and drug exposure include hospital
pharmacies, clinical laboratories and general practitioners.
Study population and validation
As glioma is not a separate code in the ICD-9-CM, all patients with
a brain tumour (ICD-9-CM code 191) in the LMR database were
linked to the Dutch nationwide network and registry of histo- and
cytopathology (PALGA) containing data of histological, cytological
and autopsy examinations of all 16 million inhabitants in the
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to 31 December 2003 to include at least 12 years of potential
medication histories since 1985. The index date was defined as the
first admission date for a brain tumour, which was (later)
confirmed to be a glioma by clinical pathology. All patients with
a previous history of nonglioma cancer before the index date were
excluded, identified by a history of cancer (ICD-9-CM codes 140-
208), a history of radiotherapy or use of anticancer medications
(ATC codes L01, L02 and L03). For each case, we took 3–4 controls
from the PHARMO database, matched on geographical region,
date of birth (5-year intervals), gender and duration of follow-up
in the PHARMO database (3-month intervals). Duration of follow-
up was defined as the difference between the date of entry in
PHARMO and the index date. Controls were assigned the same
index date as the cases and were part of the PHARMO population
on this date. To be certain that controls were free of (yet
undetected) cancer at the index date, controls with a history of
cancer up to 2 years after the index date were excluded. A history
of cancer in controls was identified as in the cases.
Exposure definition
In the Netherlands, all AHD are prescription-only drugs. For all
cases and controls, the complete history of filled prescriptions
before the index date was obtained. The following AHD were
analysed: ATC codes C02 (miscellaneous AHD), C03 (diuretics),
C07 (beta-blockers), C08 (calcium antagonists) and C09 (ACE
inhibitors and ATII antagonists). Exposure was calculated as the
duration of use before the index date in number of days, and as the
sum of dispensed defined daily doses (DDD). The DDD is the
recommended standard dose for the main indication in adults, as
defined by the World Health Organisation. As it is highly unlikely
that occasional short-term use causes glioma, we defined a prior
cutoff point of cumulative use of 6 months.
Statistical analysis
We restricted the analyses to patients aged 30 years and over. We
assessed ever use of AHD before the index date as a potential risk
factor for glioma. We compared patients and controls with respect
to cumulative duration of use and cumulative dose. Diuretics,
beta-blockers, calcium antagonists, drugs acting on the renin–
angiotensin system (ACE inhibitors, ATII antagonists) and
miscellaneous AHD were analysed separately, adjusted for the
other ATC classes. We also stratified for gender, age and
histological subgroups of glioma.
To exclude the possibility that use of AHD was started because
of symptoms in the prodromal phase of glioma, and to take into
account the delay between tumour induction and diagnosis, we
performed sensitivity analyses by subtracting a lag time of 3 years
from the index date as performed before (Beiderbeck et al, 2003).
w
2 statistics were used to compare proportions. Conditional
logistic regression was used to estimate the association between
AHD and the risk of glioma, expressed as odds ratios (ORs) and
95% confidence intervals (CI). Analyses were adjusted for residual
variation in age and duration of follow-up. Since the cumulative
Table 1 Characteristics of glioma cases and controls
Patients (n¼306) Controls (n¼1108)
Characteristic n %
a n %
a P-value
Age (years)
30–44 66 21.6 227 20.5
45–59 115 37.6 440 39.7
60–74 100 32.7 363 32.8
X75 25 8.2 78 7.0 0.84
Median, 25th–75th percentile 56.6, 47.3–67.5 56.2, 48.0–66.4
Sex
Men 184 60.1 669 60.4
Women 122 39.9 439 39.6 0.94
Follow-up time in PHARMO (years)
0t oo1 43 14.1 164 14.8
1t oo3 53 17.3 204 18.4
3t oo5 50 16.3 167 15.1
5t oo7 37 12.1 130 11.7
7t oo9 28 9.2 104 9.4
9t oo11 36 11.8 117 10.6
X11 59 19.3 222 20.0 0.99
Median, 25th–75th percentile 5.4, 2.1–10.1 5.2, 2.0–10.1
Diagnosis
Astrocytoma, glioblastoma multiforme 252 82.3
Oligodendroglioma 32 10.5
Ependymoma 3 1.0
Mixed glioma 15 4.9
Glioma not otherwise specified 4 1.3
Cumulative duration of AHD use
No use 197 64.4 804 72.6
o6 months 35 11.4 95 8.6
6 months to 4 years 40 13.1 98 8.8
X4 years 34 11.1 111 10.0 0.03
AHD: antihypertensive drugs.
aPercentages may deviate from 100% due to rounding.
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short-term high-dose AHD, we also adjusted for duration of use in
the analyses for cumulative dose. In the analyses for cumulative
duration of use, we additionally adjusted for mean DDD per day of
use. All statistical tests were performed two-sided and statistical
significance was indicated if Po0.05. Analyses were performed
using SPSS for Windows version 12.0.1 and Statistical Analysis
System version 8.2.
RESULTS
The baseline characteristics of 306 glioma patients and 1108
matched controls aged over 30 years are shown in Table 1. The
most frequent subtype was astrocytic glioma (82.3%), followed
by oligodendroglioma (10.5%) and mixed glioma (4.9%), this
distribution and the male excess (60.1%) being comparable with
those previously reported (van der Sanden et al, 1998; Kleihues
and Cavenee, 2000). The median follow-up time in PHARMO was
5.4 years for patients and 5.2 years for controls. The cumulative
duration of AHD use was longer in patients than in controls
(P¼0.03).
In the conditional logistic regression analyses, an increased risk
of glioma was found for users of any AHD (OR 1.45; 95% CI 1.03–
2.04) (Table 2). When exposure was measured as cumulative dose,
a nonsignificantly increased risk was found for users who received
4180 DDD compared with users who received o180 DDD (OR
1.35; 95% CI 0.86–2.11). After stratification for ATC classes, none
of the other risk estimates reached statistical significance, although
numbers were small in some of the exposure categories (Table 2).
The risk of glioma was elevated for users of miscellaneous AHD
(OR 1.96; 95% CI 0.71–5.37), but not significantly.
Comparable risks were seen when exposure was measured as
cumulative dose (not shown). Again, a nonsignificantly increased
risk was found for users of miscellaneous AHD (OR 2.05; 95% CI
0.65–6.49). These results did not change when adjusted for the
mean DDD per day of use (not shown).
In the sensitivity analyses, subtracting 3 years from the index
date moved the risk estimates toward unity (Table 3), and no
increased risk for users of any AHD could be shown (OR 1.08; 95%
CI 0.69–1.70).
We also stratified for diagnosis (astrocytoma only, oligoden-
droglioma only), gender and age, and analysed for the use of any
AHD. This did not change the results (not shown). In particular,
no association was found for elderly men, who have the highest
prevalence of hypertension (Houben et al, 2004).
DISCUSSION
This is the first detailed study of the effect of AHD use on glioma
risk, using prospectively collected automated pharmacy data. The
higher risk of glioma for users of any AHD disappeared when a lag
time of 3 years was applied; none of the different classes of AHD
showed statistically significant associations.
An association between AHD-use and cancer risk is not
established. There is evidence that renal carcinoma is associated
with diuretic use (Grossman et al, 2001), although this is not
generally accepted (Choi et al, 2005; Fryzek et al, 2005). Prenatal
exposure to diuretics was associated with an increased risk of
childhood brain tumours (Preston-Martin et al, 1982), which could
not be confirmed by subsequent studies (Kuijten et al, 1990;
McCredie et al, 1994; McKean-Cowdin et al, 2003). The risks of
exposure to AHD in adulthood have not been thoroughly
investigated although no increased risk could be shown for
diuretic use (Ryan et al, 1992). No association was found between
blood pressure and brain tumours, but numbers of cases were
small, the effect of AHD was not investigated, and gliomas were not
studied as a separate group (Batty et al, 2003).
We previously found a higher prevalence of hypertension in
glioma patients (Houben et al, 2004). Since glioma is not known to
induce clinically relevant hypertension and because hypertension
is not a known risk factor for glioma, we hypothesised that the use
of AHD might be the link in the observed association. The results
Table 2 Associations between the duration of use of antihypertensive drugs and glioma, without considering a lag period of exposure
Patients Controls
Exposure n % n % Adjusted OR
a 95% CI Adjusted OR
b 95% CI
Any AHD
o6 months 232 75.8 899 81.1 Reference
X6 months 74 24.2 209 18.9 1.45 1.03–2.04
Diuretics
o6 months 283 92.5 1034 93.3 Reference
X6 months 23 7.5 74 6.7 1.13 0.68–1.89 0.87 0.50–1.50
Beta-blockers
o6 months 268 87.6 995 89.8 Reference
X6 months 38 12.4 113 10.2 1.27 0.84–1.91 1.18 0.75–1.86
Calcium antagonists
o6 months 287 93.8 1045 94.3 Reference
X6 months 19 6.2 63 5.7 1.00 0.58–1.74 0.68 0.38–1.23
Ace inhibitors, ATII antagonists
o6 months 274 89.5 1021 92.1 Reference
X6 months 32 10.5 87 7.9 1.39 0.89–2.19 1.28 0.78–2.10
Miscellaneous AHD
o6 months 299 97.7 1097 99.0 Reference
X6 months 7 2.3 11 1.0 2.40 0.91–6.37 1.96 0.71–5.37
AHD: antihypertensive drugs; OR: odds ratio; CI: confidence interval.
aAdjusted for age, gender and duration of follow-up.
bAdjusted for age, gender, duration of follow-up and
for use of other types of antihypertensive drugs (ever vs never use).
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associations disappeared in the sensitivity analyses, suggesting that
hypertension is part of the prodromal signs of glioma prompting
prescription of AHD though it must be conceded that such a
presentation of glioma is not recognised.
Major strengths of this study are its population-base and its use
of prospectively collected data on drug exposure and pathology.
Pharmacy records are more complete and more reliable than
medical records or patient interviews, thereby avoiding recall bias
(Paganini-Hill and Ross, 1982). It has been shown that compu-
terised pharmacy records are a reliable source of true current drug
exposure (Lau et al, 1997), and that any misclassification is
nondifferential, leading to underestimation of the true effect,
rather than the reverse, in pharmaco-epidemiological studies (Lau
et al, 1997). We considered information about glioma diagnosis to
be reliable since several sources were combined, including PALGA,
which is not only used for research purposes but for daily patient
care. Detection bias seems unlikely as gliomas will almost always
become symptomatic, regardless of medical surveillance. We
therefore did not adjust for the effect of medical attention due to
comorbidity, but did adjust for gender, age, duration of follow-up
and geographical region. Because the PHARMO database does not
contain information on lifestyle variables, we were not able to
adjust for obesity, smoking or alcohol use. However, we do not
expect this to be a problem since none of these factors has been
associated with glioma (Wrensch et al, 2002).
A potential problem is that the duration of observation might
have been too short to study the influence of AHD on glioma risk,
possibly leading to an underestimation of risk. Furthermore, we
studied five categories of AHD, based on the main mode of action.
Within these categories, however, drugs can have different modes
of action. For instance, ACE inhibitors and angiotensin II
inhibitors are both classified in ATC group C09, but might differ
in their ability to induce or promote glioma. The numbers of cases
were too small to analyse these AHD separately. Similarly, for the
group of miscellaneous AHD, numbers of cases were too small to
draw conclusions.
In conclusion, a causal association between AHD and glioma
seems unlikely, although we cannot exclude the possibility that
AHD modify the occurrence of glioma. Both overall exposure and
exposure to subgroups of AHD could not be clearly related to a
higher risk of glioma. Some associations disappeared in the
sensitivity analyses, indicating that hypertension might be a
prodromal sign of glioma.
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